Monoclonal immunoglobulin light and heavy chain deposition diseases: Molecular models of common renal diseases

Contributions to Nephrology

Volumn 169, Issue , 2011, Pages 221-231

  Ronco, Pierre ^a,b,c   Plaisier, Emmanuelle ^a,b,c   Aucouturier, Pierre ^a,d  

^a SORBONNE UNIVERSITÉ   (France)

^b Urgences Néphrologiques et Transplantation Rénale Hôpital Tenon 4   (France)

^c HÔPITAL TENON   (France)

^d HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN;

ARTICLE; CHEMICAL STRUCTURE; EXTRACELLULAR MATRIX; FIBROSIS; GLOMERULUS; HUMAN; IMMUNOLOGY; KIDNEY DISEASE; METABOLISM; PATHOLOGY;

EXTRACELLULAR MATRIX; FIBROSIS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY DISEASES; KIDNEY GLOMERULUS; MODELS, MOLECULAR;

EID: 84925933637     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000314778     Document Type: Article

References (45)

1. Buxbaum JN, Chuba JV, Hellman GC, Solomon A, Gallo GR: Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med 1990;112:455-464.
2. Preudhomme JL, Aucouturier P, Touchard G, Striker L, Khamlichi AA, Rocca A, Denoroy L, Cogne M: Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int 1994;46:965-972.
3. Kobernick SD, Whiteside JH: Renal glomeruli in multiple myeloma. Lab Invest 1957;6:478-485.
4. Sanchez LM, Domz CA: Renal patterns in myeloma. Ann Intern Med 1960;52:44-54.
5. Antonovych TT, Lin RC, Parrish E, Mostofi K: Light chain deposits in multiple myeloma (abstract). Lab Invest 1974;30:370A.
6. Randall RE, Williamson WC Jr, Mullinax F, Tung MY, Still WJ: Manifestations of sys temic light chain deposition. Am J Med 1976;60:293-299.
7. Preudhomme JL, Morel- Maroger L, Brouet JC, Mihaesco E, Mery JP, Seligmann M: Syn thesis of abnormal heavy and light chains in multiple myeloma with visceral deposition of monoclonal immunoglobulin. Clin Exp Immunol 1980;42:545-553.
8. Aucouturier P, Khamlichi AA, Touchard G, Justrabo E, Cogne M, Chauffert B, Martin F, Preudhomme JL: Brief report: heavy chain deposition disease. N Engl J Med 1993;329: 1389-1393.
9. Moulin B, Deret S, Mariette X, Kourilsky O, Imai H, Dupouet L, Marcellin L, Kolb I, Aucouturier P, Brouet JC, Ronco PM, Mougenot B: Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking CH1. J Am Soc Nephrol 1999;10:519-528.
10. Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, DAgati VD:Renal monoclonal immunoglobulin dep osition disease: the disease spectrum. J Am Soc Nephrol 2001;12:1482-1492.
11. Kambham N, Markowitz GS, Appel GB, Kleiner MJ, Aucouturier P, Dagati VD: Heavy chain deposition disease: the disease spectrum. Am J Kidney Dis 1999;33:954-962.
12. Khamlichi AA, Rocca A, Touchard G, Aucouturier P, Preudhomme JL, Cogne M: Role of light chain variable region in mye loma with light chain deposition disease: evidence from an experimental model. Blood 1995;86:3655-3659.
13. Soma J, Sato K, Sakuma T, Saito H, Sato H, Sato T, Abbas A, Aucouturier P: Immunoglobulin gamma3- heavychain deposition disease: report of a case and relationship with hypocomplementemia. Am J Kidney Dis 2004;43:E10-E16.
14. Ronco P, Plaisier E, Mougenot B, Aucouturier P: Immunoglobulin light (heavy)- chain deposition disease: from molecular medicine to pathophysiology- driven therapy. Clin J Am Soc Nephrol 2006;1:1342-1350.
15. Preudhomme JL, Morel- Maroger L, Brouet JC, Cerf M, Mignon F, Guglielmi P, Seligmann M: Synthesis of abnormal immunoglobulins in lymphoplasmacytic disorders with visceral light chain deposition. Am J Med 1980;69:703-710. (Pubitemid 11241346)
16. Solomon A, Weiss DT, Kattine AA: Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991;324:1845-1851.
17. Denoroy L, Deret S, Aucouturier P: Overrepresentation of the VkappaIV subgroup in light chain deposition disease. Immunol Lett 1994;42:63-66.
18. Cogné M, Preudhomme JL, Bauwens M, Touchard G, Aucouturier P: Structure of a monoclonal kappa chain of the VkappaIV subgroup in the kidney and plasma cells in light chain deposition disease. J Clin Invest 1991;87:2186-2190.
19. Khamlichi AA, Aucouturier P, Silvain C, Bauwens M, Touchard G, Preudhomme JL, Nau F, Cogne M: Primary structure of a monoclonal kappa chain in myeloma with light chain deposition disease. Clin Exp Immunol 1992;87:122-126.
20. Rocca A, Khamlichi AA, Aucouturier P, Noel LH, Denoroy L, Preudhomme JL, Cogne M: Primary structure of a variable region of the VkappaI subgroup (ISE) in light chain deposition disease. Clin Exp Immunol 1993;91:506-509.
21. Bellotti V, Stoppini M, Merlini G, Zapponi MC, Meloni ML, Banfi G, Ferri G: Amino acid sequence of k Sci, the Bence Jones protein isolated from a patient with light chain deposition disease. Biochim Biophys Acta 1991;1097:177-182.
22. Deret S, Chomilier J, Huang DB, Preudhomme JL, Stevens FJ, Aucouturier P: Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non- amyloid light chain deposition disease. Protein Eng 1997;10:1191-1197.
23. Ganeval D, Noel LH, Preudhomme JL, Droz D, Grunfeld JP: Light- chain deposition disease: its relation with AL- type amyloidosis. Kidney Int 1984;26:1-9.
24. Khurana R, Gillespie JR, Talapatra A, Minert LJ, Ionescu- Zanetti C, Millett I, Fink AL: Partially folded intermediates as critical pre cursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry 2001;40: 3525-3535.
25. Husby G, Blichfeldt P, Brinch L, Brandtzaeg P, Mellbye OJ, Sletten K, Stenstad T: Chronic arthritis and gamma heavy chain disease: coincidence or pathogenic link? Scand J Rheumatol 1998;27:257-264.
26. Cheng IK, Ho SK, Chan DT, Ng WK, Chan KW: Crescentic nodular glomerulosclerosis secondary to truncated immunoglobulin alpha heavy chain deposition. Am J Kidney Dis 1996;28:283-288.
27. Ronco PM, Alyanakian MA, Mougenot B, Aucouturier P: Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol 2001;12:1558-1565.
28. Khamlichi AA, Aucouturier P, Preudhomme JL, Cogne M: Structure of abnormal heavy chains in human heavy chain deposition disease. Eur J Biochem 1995;229:54-60.
29. Keeling J, Teng J, Herrera GA: ALamyloidosis and light- chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest 2004;84:1322-1338.
30. Teng J, Russell WJ, Gu X, Cardelli J, Jones ML, Herrera GA: Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest 2004;84:440-451.
31. Keeling J, Herrera GA: Matrix metalloproteinases and mesangial remodeling in light chain- related glomerular damage. Kidney Int 2005;68:1590-1603.
32. Keeling J, Herrera GA: An in vitro model of light chain deposition disease. Kidney Int 2009;75:574-576.
33. Bruneval P, Foidart JM, Nochy D, Camilleri JP, Bariety J: Glomerular matrix proteins in nodular glomerulosclerosis in association with light chain deposition disease and diabetes mellitus. Hum Pathol 1985;16:477-484.
34. Stokes MB, Holler S, Cui Y, Hudkins KL, Eitner F, Fogo A, Alpers CE: Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease. Kidney Int 2000;57:487-498.
35. Truong LD, Pindur J, Barrios R, DAgati V, Lechago J, Suki W, Majesky M: Tenascin is an important component of the glomerular extracellular matrix in normal and pathologic conditions. Kidney Int 1994;45:201-210.
36. Zhu L, Herrera GA, Murphy- Ullrich JE, Huang ZQ, Sanders PW: Pathogenesis of glomerulosclerosis in light chain deposition disease: role of transforming growth factor- beta. Am J Pathol 1995;147:375-385.
37. Russell WJ, Cardelli J, Harris E, Baier RJ, Herrera GA: Monoclonal light chain-mesangial cell interactions: Early signaling events and subsequent pathologic effects. Lab Invest 2001;81 :689-703.
38. Komatsuda A, Wakui H, Ohtani H, Kodama T, Miki K, Imai H, Miura AB: Disappearance of nodular mesangial lesions in a patient with light chain nephropathy after long- term chemotherapy. Am J Kidney Dis 2000;35:E9.
39. Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I, Ronco P, Brouet JC, Fermand JP: High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004;65:642-648.
40. Hassoun H, Flombaum C, DAgati VD, Rafferty BT, Cohen A, Klimek VM, Boruchov A, Kewalramani T, Reich L, Nimer SD, Comenzo RL: High- dose melphalan and auto- SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant. 2008;42:405-412.
41. Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N: Long- term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 2008;23:2052-2057.
42. Leung N, Lager DJ, Gertz MA, Wilson K, Kanakiriya S, Fervenza FC: Longterm outcome of renal transplantation in light- chain deposition disease. Am J Kidney Dis 2004;43:147-153.
43. Dussaule JC, Chatziantoniou C: Reversal of renal disease: is it enough to inhibit the action of angiotensin II? Cell Death Differ 2007;14:1343-1349.
44. Ostendorf T, Rong S, Boor P, Wiedemann S, Kunter U, Haubold U, van Roeyen CR, Eitner F, Kawachi H, Starling G, Alvarez E, Smithson G, Floege J: Antagonism of PDGF- D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2006;17:1054-1062.
45. Picken MM: The role of mesangial homeostasis in glomerular injury progression: hope for mesangial sclerosis reversal. Kidney Int 2009;75:574-576.